Personalised Patient Diagnosis and Prognosis in Prostate Cancer: What Are the Future Perspectives?  Luis Martínez-Piñeiro  European Urology Supplements  Volume 9, Issue 11, Pages 794-799 (December 2010) DOI: 10.1016/j.eursup.2010.10.003 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Relationship between prostate cancer gene 3 (PCA3) score and prostate tumour volume assessed after radical prostatectomy. Reproduced with permission from Nakanishi et al [21]. European Urology Supplements 2010 9, 794-799DOI: (10.1016/j.eursup.2010.10.003) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 Receiver operator curves for predicting extracapsular extension by preoperative serum prostate-specific antigen (PSA), prostate cancer gene 3 (PCA3) score, and biopsy Gleason score (bGS). Reproduced with permission from Whitman et al [22]. LR = logistic regression; AUC = area under the curve. European Urology Supplements 2010 9, 794-799DOI: (10.1016/j.eursup.2010.10.003) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 3 Development of gene fusions in prostate cancer that occur through translocation (TMPRSS2:ETV1) or chromosomal deletion (TMPRSS2:ERG). Reproduced with permission from Tomlins et al [25]. European Urology Supplements 2010 9, 794-799DOI: (10.1016/j.eursup.2010.10.003) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 4 Kaplan-Meier estimates of probabilities of overall survival of castration-resistant prostate cancer patients with favourable (<5) and unfavourable (≥5) circulating tumour cells (CTCs). Reproduced with permission from de Bono et al [32]. European Urology Supplements 2010 9, 794-799DOI: (10.1016/j.eursup.2010.10.003) Copyright © 2010 European Association of Urology Terms and Conditions